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Abstract
Background: High levels of SOX2 protein are correlated with increased dissemination of breast cancer. However,
the underlying molecular mechanisms are not fully understood.
Methods: In this study we investigate the role of SOX2 in breast cancer metastasis using multiple in vitro and
in vivo assays including cell culture, shRNA-mediated knockdown, wound healing, colony formation, transwell
chamber, xenograft and tail vein injection. Moreover, western blot, immunostaining, microarray and real-time PCR
were used to determine the change of protein and miRNA levels. Luciferase assays were also used to evaluate
activity which TUSC3 is a target of miR-181a-5p and miR-30e-5p, and the clinical survival relevance was analyzed by
Kaplan-Meier analysis.
Results: We identified a novel pathway involving SOX2 regulation of microRNAs to control the proliferation and
migration of breast cancer cells. shRNA-mediated knockdown of SOX2 inhibits breast cancer cell expansion and
migration. More importantly, we found that these changes are accompanied by significant reduction in the levels
of two microRNAs, miR-181a-5p and miR-30e-5p. Overexpression of these two microRNAs leads to reduced protein
levels of Tumor Suppressor Candidate 3 (TUSC3) in breast cancer cells; mutations of the potential binding sites in the
3’-UTR of TUSC3 abrogate the inhibitory effects of the microRNAs. We further found that upregulation of TUSC3
expression leads to reduced proliferation and migration of breast cancer cells. In human breast cancer samples the
levels of TUSC3 protein are inversely correlated with those of SOX2 protein.
Conclusions: Taken together, our work reveals a novel SOX2-mediated regulatory axis that plays critical roles in the
proliferation, migration and invasiveness of breast cancer cells. Targeting this axis may provide beneficial effect in the
treatment of breast cancer.
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Background
Breast cancer is a leading cause of cancer-related death
in women worldwide. Despite the significant progress
that has been made in cancer treatment and early detec-
tion, approximately 30 to 70% of breast cancer patients
die from breast cancer recurrence or metastasis [1].
Therefore it is important to investigate the mechanisms
underlying cancer cell proliferation and metastasis-
related cellular activities such as cell migration and inva-
sion. Genetic mutations or epigenetic modifications that
provide growth advantage are critical for tumour initi-
ation and progression. In breast cancer, activation muta-
tions of genes such as EGFR, HER2 have been found to
transmit signals into the nucleus to up-regulate the tran-
scription of downstream genes, promoting cancer cell
growth [2–4]. However, little is known about the media-
tors in the nucleus that are involved in gene regulation.
Interestingly, the transcription factor SOX2 has recently
been associated with breast cancer formation and metas-
tasis [5]. SOX2 belongs to the sex determining region Y
(SRY)-like box (SOX) gene family, members of which
are pivotal for normal development and maintenance of
stemness [6–11], cell proliferation and differentiation
[12]. Emerging studies demonstrated that the SOX2 pro-
tein is also involved in tumourigenesis [13–15]. High
levels of SOX2 closely correlate with multiple processes
during tumour development, including initiation [16],
maintenance [17, 18], invasion and metastasis [19–21].
Accordingly, aberrant SOX2 expression was detected in
multiple types of cancers at different stages. We and
others have shown high levels of SOX2 in lung cancer,
esophageal squamous cell carcinomas (ESCC) and ovarian
cancer [13, 22–26]. Interestingly, high levels of SOX2
proteins have also been found in 19% of breast cancer pa-
tients [5]. Moreover, SOX2 expression has been linked to
tamoxifen resistance and relapse in breast cancer treat-
ment [27]. Nevertheless, the mechanisms by which high
levels of SOX2 regulate the progression and metastasis of
breast cancer remain largely unexplored.
MicroRNAs (miRNAs) are small, noncoding RNAs
that are important for the regulation of gene expressions
at the post-transcriptional level. miRNAs are involved in
almost all key cellular activities such as proliferation,
differentiation and migration [28]. Dysregulation of miR-
NAs is also involved in the initiation and progression of
human cancers including breast cancer [29–31]. For ex-
ample, miR-124 is down-regulated in breast cancer cell
lines. Ectopic expression of miR-124 reduces the protein
levels of Myc and phospho-Rb while up-regulating p27
in the breast cancer cell line MDA-MB-231 [32], sug-
gesting that miRNAs function as a tumour suppressor.
In this study we examined the molecular mechanisms
used by SOX2 in the proliferation and migration of
breast cancer cell lines and identified that SOX2
regulates two miRNAs (miR-181a-5p and miR30e-5p)
which in turn influence the expression of a common
downstream target TUSC3. Importantly, inversed ex-
pression of SOX2 and TUSC3 is associated with poor
prognosis of a subpopulation of breast cancer patients.
Therefore we demonstrate here a clinically relevant axis
which involves SOX2/miRNAs/TUSC3 in breast cancer
development.
Methods
Cell lines and mice
ZR7530 (Cat NO: CRL-1504™) and MDA-MB-231
(Cat NO: HTB-26™) breast cancer cell lines were pur-
chased from ATCC (Manassas, VA, USA), Cell line
authentication was conducted by short tandem repeat
analysis, and mycoplasma contamination in cell lines
was tested using multiplex PCR. They were infected
with lentivirus carrying pLK0.1SOX2 (SOX2 knock-
down plasmid), pCDH-SOX2-IRES-GFP (SOX2 overex-
pression plasmid), pLK0.1Scramble (control plasmid)
[33], and pCDH-TUSC3-IRES-GFP (TUSC3 overex-
pression plasmid, primers used for construction were
shown in Additional file 1: Table S1). Puromycin
(Santa Cruz Biotechnology, Cat No: sc-108071, Dallas,
TX, USA) selection was used to establish cell lines
stably expressing these constructs. Cell lines were cul-
tured in Dulbecco’s Modified Eagle Medium (DMEM,
HyClone, Cat No: SH30022.01B, Beijing, China) with
10% foetal bovine serum (FBS, Gibco, Cat No:10270-106,
Grand Island, NY, USA). Nude mice at 6-weeks old
were purchased from SLRC Laboratory Company
(Shanghai, China).
Western blot analysis
Western blot was performed as previously described
[34]. PVDF membrane was used for protein transfer and
probed with antibodies against human SOX2 (polyclonal
rabbit anti-SOX2, SEVEN HILLS, Cat No: WRAB-1236,
Cincinnati, USA), human β-actin (mouse anti-β-actin,
Beyotime, Cat No: AA128, Nantong, China), CDK4
(BBI, Cat No: AB20396b, Shanghai, China), CDK6 (BBI,
Cat No: AB20398a, Shanghai, China), CCND1 (BBI, Cat
No: AB60236b, Shanghai, China), TUSC3 (Novus
Biologicals, Cat No: NBP1-55630, Littleton, USA).
HRP-conjugated goat anti-rabbit IgG (Abcam, Cat No:
ab136817, Cambridge, MA, USA) and HRP-conjugated
goat anti-mouse IgG (ZSGB-Bio, Cat No: ZB-2305,
Beijing, China) were used as secondary antibodies to
detect the proteins. The density of protein band was
quantified with Image-Pro Plus 6.0 software, and the
ratio of target protein to housekeeping protein, which
reflects the change of expression level, was calculated.
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Cell proliferation and colony formation assays
ZR7530 or MDA-MB-231 cells with genetic manipula-
tion (knockdown or overexpression) were seeded in 96-
well plates. The OD value of cells was measured under
450 nm and 630 nm at 24, 48, 72 and 96 h using the Cell
Counting Kit 8 (CCK-8) (Beyotime) assay, and the
absorbance difference between 450 nm and 630 nm rep-
resents cell proliferation rates. For soft agar colony
formation assays, ZR7530 or MDA-MB-231 cells were
seeded in 6-well plates and maintained for 2 weeks and
colonies were fixed with 4% paraformaldehyde (DingGuo,
Cat No: AR-0211, Beijing, China) and stained with 0.5%
crystal violet. The number of total colonies and colonies
with a diameter greater than 0.5 mm were calculated with
Image J (Fiji-win32 software, University of Wisconsin-
Madison), and the data were analysed as previously
described [35, 36].
Wound healing assay
1 × 106 ZR7530 or MDA-MB-231 cells (SOX2 knock-
down, scramble and TUSC3 overexpression) were seeded
in 6-well plates and grown to 90% confluence. Cell mono-
layers were scraped with a sterile pipette tip. Floating cells
were removed and the cultures were maintained in
DMEM supplemented with 5% FBS. The wound area was
recorded 0 h and 48 h after the scrape. The healing index
was calculated and analysed using the formula: (S0 − Sn)/
S0 × 100%, which represents the ability of cellular migra-
tion. S0 represents the blank area 0 h after scraping, and
Sn represents the blank area n h after scraping [37].
Matrigel invasion assay
Invasion assays were performed in chambers with a 6.5-
mm insert in 24-well plates (Corning company, Cat No:
3422, Corning, NY, USA). An 8-μm polycarbonate mem-
brane was coated with 12 μl of ice-cold Matrigel™ Base-
ment Membrane Matrix (BD company, Cat No: 356234,
Bedford, MA, USA). Cells (5x104 per well) were added
to the upper chamber in 200 μl of the medium contain-
ing 5% FBS. The lower chamber was filled with 500 μl of
medium containing 20% FBS. The culture was main-
tained for 24 h. Cells were then fixed in methanol and
stained with 1% crystal violet. Cells at the lower side of
the filter were counted under a light microscope and
dissolved with 50% acetic acid.
Xenograft studies
1x105 ZR7530 cells were re-suspended in 200 μl of
DMEM and subcutaneously injected into the flanks of
6-week old BALB/c nude mice, which were maintained
in the SPF environment. Five female nude mice per co-
hort (SOX2 knockdown and control) were randomly di-
vided to receive cancer cells. Tumour size was measured
every 3 days using a Vernier calliper after injection, and
tumour volumes were calculated with the formula
0.52 × width2 × length [38, 39]. Tumours were collected
7 weeks after cell inoculation.
For lung metastatic experiments, 2 × 106 tumour cells
were re-suspended in 100 μl of PBS and injected into
BALB/c nude mice via the tail vein. Five female nude
mice per cohort, which were also maintained in the SPF
environment, received the tumour cells through tail vein.
These nude mice were sacrificed 8 weeks after tail vein
injection. Lungs were fixed with 4% PFA and sectioned
for haematoxylin and eosin (HE) staining to determine
the metastatic capabilities of cancer cells. The meta-
static capabilities were assessed as previously described
[40, 41].
miRNA microarray assay and real-time PCR
Total RNAs of ZR7530 cells (SOX2 knockdown and con-
trol) were extracted and purified using Trizol (Invitrogen,
Carlsbad, CA, USA) and miRNeasy kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol. The
human miRNA microarray miRCURY™ LNA Expression
Array (v.18.0, Exiqon) was used to detect the level changes
after SOX2 knockdown. The low intensity miRNAs were
filtered, and original signal intensities were normalised
using the Median Normalization Method. The miRNA
data were analysed with Significance Analysis of Microar-
rays (SAM) version 2.1 to generate a list of miRNAs that
up-regulate or down-regulate with a fold change ≥1.5 and
a p-value ≤0.05. Quantitative real-time PCR analysis was
used to validate the level changes of miRNA. Additional
file 1: Table S2 and Table S3 describe the stem-loop RT
primers and specific PCR primers used for quantitative
PCR.
GO and pathway analyses
Differentially expressed miRNAs were clustered using
the Cluster software, and we performed miRNA target
gene predictions using the microRNA target prediction
tools miRBase, TargetScan, and miRanda, and all com-
mon target genes which are regulated by two or mul-
tiple miRNAs were analyzed with cytoscape program.
We also performed Gene Ontology (GO) analysis
(http://www.geneontology.org) of the target genes that
were predicted using the three databases, and the
KEGG database (http://www.genome.jp/kegg/) was se-
lected for pathway analysis based on the target genes of
these differentially expressed miRNAs. The significance
of the GO terms and Pathway was selected based on a
p-value cut-off of 0.05.
Luciferase reporter assays
Luciferase reporter activities were determined using the
Dual-Luciferase Reporter Assay System (Promega, Cat
No. E1910, Madison, USA). The primers used for
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obtaining mutated 3’UTR of TUSC3 were described in
Additional file 1: Table S4. pGL3 with wild-type or mu-
tated 3’UTR of TUSC3, miRNA mimics and pRL-TK were
co-transfected into cells for all luciferase assays, and
Renilla luciferase activities were measured to assess the
transfection efficiency, sequences of miRNA mimics, in-
hibitors and relevant controls were shown in Additional
file 1: Table S5.
Statistical analysis
The data represent at least three independent experi-
ments using cells or extracts from a minimum of three
separate isolations. Differences between groups were
compared using analysis of variance for repeated mea-
sures. All statistical analyses were performed using
GraphPad PRISM. v5.0 software (San Diego, CA, USA).
Data were presented as mean ± SD (standard deviation).
Statistical significance between two groups was calcu-
lated by unpaired student’s t-test, and P value < 0.05 is
considered significant.
Results
SOX2 knockdown leads to reduced proliferation and
migration of breast cancer cells
The breast cancer cells ZR-7530 and MDA-MB-231 ex-
press high levels of SOX2 protein. To test whether
SOX2 is required for the proliferation of these cell lines,
we performed lentivirus-delivered SOX2 shRNA knock-
down in ZR-7530 as previously described [33]. Knock-
down leads to up to 85–92% reduction in the levels of
SOX2 protein (p < 0.01 for ZR-7530 and p < 0.001 for
MDA-MB-231) (Fig. 1a). More importantly, decreased
protein levels are associated with decreased prolifera-
tion of cancer cells, especially 96 h after knockdown
(p < 0.001 for ZR-7530 and p < 0.001 for MDA-MB-
231) (Fig. 1b). The decrease in cell proliferation is cor-
related with reduced levels of cell cycle protein
CCND1, CDK4 and CDK6 (Fig. 1d). Similarly, SOX2
knockdown inhibits the proliferation of MDA-MB-231
cells (Fig. 1b right). We also performed colony forming
assay to test whether SOX2 knockdown affects colony
formation from single cells. Reduced levels of SOX2
affect the number and size of colonies. The number of
colonies with a diameter greater than 0.5 mm formed
from ZR7530 knockdown cells was significantly re-
duced in the SOX2-knockdwon (SOX2-Kd) group
compared to scramble controls (P < 0.05) (Fig. 1c).
Similarly, SOX2 knockdown in MDA-MB-231 cells
also significantly reduced the number of colonies with
diameters greater than 0.5 mm (P < 0.05). Together
these data confirm that SOX2 is required for the pro-
liferation of breast cancer cells.
High levels of SOX2 have been found in metastasized
breast cancer nodules [42]. We next asked whether SOX2
is involved in cellular activities (e.g. cell migration) rele-
vant to metastasis. SOX2 knockdown results in a decrease
in the migration capability of ZR7530 and MDA-MB-231
cells (Fig. 2a). Wound-healing assay showed that the heal-
ing index was reduced from 24.75% (controls) to 3.33%
for ZR7530 cells (p < 0.001), and from 57.39 to 43.8% for
MDA-MB-231 cells (p < 0.05) (Fig. 2b). In addition, SOX2
knockdown inhibits the invasion of breast cancer cells in
transwell assay. The number of cancer cells passing
through the filter of the transwell are significantly re-
duced after SOX2 knockdown (Fig. 2c, d, p < 0.01 for
ZR7530 and p < 0.05 for MDA-MB-231). The changed
tendency of the OD value of eluted crystal violet was
consistent with the number of migrated cells in these
groups (p < 0.01 for ZR7530 and p < 0.05 for MDA-
MB-231) (Fig. 2e). Together, these in vitro results dem-
onstrate that high levels of SOX2 protein are critical
for migration and invasion of breast cancer cells.
SOX2 level changes are correlated with tumour
development and metastasis in murine xenograft models
We next used a xenograft model to test whether SOX2
knockdown reduces tumour growth in vivo. SOX2
knockdown ZR7530 and control cells were transplanted
into immunocompromised nude mice. Significantly,
SOX2 knockdown leads to 4.4 and 4.7 fold decreases
in the volume and weight of tumour, respectively
(Fig. 3a–c) (n = 5). In addition, SOX2 overexpression
enables higher tumourigenesis capability of breast
cancer cells. We transplanted SOX2-overexpressing
ZR7530 cells into nude mice, and SOX2 overexpres-
sion results in a 2.3 fold increase in tumour volume
and a 3.6 fold increase in tumour weight (Fig. 3a–c)
(n = 5). These results suggest that the levels of SOX2
are correlated with increased growth capability of
breast cancer cells in vivo.
Our in vitro results show that SOX2 knockdown re-
duces the migration of breast cancer cell lines. To test
whether decreased levels of SOX2 also block metasta-
sis capability in vivo, we performed tail vein injection
of ZR7530 and studied tumour seeding and develop-
ment in the lung. Upon SOX2 knockdown, the number
of tumours seeded in the lung are significantly reduced
(33 ± 2 Vs 7 ± 3) (p < 0.001) (n = 5) (Fig. 3d, e). In
addition, SOX2 knockdown also reduces the ratio of
tumour/total lung area (10.4% Vs 1.8%) (p < 0.001)
(Fig. 3f ). By contrast, ectopic SOX2 expression enables
high metastastic capability of ZR7530 cells, leading to
an increased number of seeding tumours (33 ± 2 Vs 51 ± 4)
(p < 0.01) and enlarged metastatic foci in the lung (10.4%
vs 27.5%) (p < 0.001) (Fig. 3d–f). Together, these in vivo
findings support the important roles of SOX2 in promoting
metastasis of breast cancer cells.
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SOX2 knockdown leads to decreased levels of miR-181a-5p
and miR-30e-5p
miRNAs have been implicated in the regulation of mul-
tiple steps in breast cancer progression [43–45]. To test
whether SOX2 regulates proliferation and metastasis
through miRNAs, we performed microRNA microarray
analysis (miRCURY™ LNA Expression Array v.18.0,
Exiqon). Total RNAs were isolated from scramble control
and SOX2 knockdown ZR7530 cells. SOX2 knockdown
significantly changed the levels of multiple miRNAs, among
which 11 were up-regulated and 10 were significantly
down-regulated (Fig. 4a and Additional file 1: Table S6,
p < 0.05). We validated the expression levels with real-
time PCR (Fig. 4b). Although the levels of miR-338-3p
are significantly down-regulated in the array analysis,
the levels of miR-30e-5p are most dramatically down-
regulated upon SOX2 knockdown, which was validated
by real-time PCR (Fig. 4b). Notably, the levels of miR-
181a-5p which has previously been associated with breast





Fig. 1 SOX2 knockdown leads to reduced proliferation of breast cancer cells. a SOX2 knockdown leads to significant reduction in the levels of
SOX2 protein in ZR7530 and MDA-MB-231 cells. b SOX2 knockdown inhibits the proliferation of breast cancer cell lines ZR7530 and MDA-MB-231.
c Decrease in the levels of SOX2 in breast cancer cells results in reduced colony formation efficiency and colony size. d SOX2 knockdown reduces
the levels of cell cycle regulators CDK6, CDK4 and Cyclin D1 (CCND1). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001 vs control,
and the error bars indicate the mean ± standard deviation (SD)
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(Fig. 4a, b) [46]. Down-regulation of miR-30e-5p and miR-
181a-5p was also observed in MDA-MB-231 cells after
SOX2 knockdown (data not shown).
miR-181a-5p and miR-30e-5p co-regulate TUSC3 in breast
cancer cells
Several miRNAs down-regulated upon SOX2 knock-
down, have been implicated in the regulation of genes
involved in metabolism, signalling pathway activation
(Fig. 4c, d). Intriguingly, miR-181a-5p and miR-30e-5p
share a common downstream target, TUSC3 as identi-
fied by the cytoscape program. TUSC3 is a putative
tumor suppressor gene, and hypermethylation or loss of
this gene has been found in cancers such as ovarian and
breast cancer [47–49]. Intriguingly, two potential bind-
ing sites of miR-181a-5p and miR-30e-5p were identified
at the 3’-UTR of TUSC3 (Fig. 5a). Consistently, transfec-
tion of miR-181a-5p or miR-30e-5p mimics reduces the
protein levels of TUSC3 in ZR7530 cells (Fig. 5b). Con-
versely, inhibition of these two miRNAs with specific in-
hibitors leads to increased protein levels of TUSC3
(Fig. 5c). We then cloned the 3’-UTR of TUSC3 contain-
ing the potential miRNA binding sites into the luciferase
reporter vectors and tested whether these two miRNAs
regulate TUSC3 through the potential binding sites
(Fig. 5d, Additional file 2: Figure S1). Interestingly, co-
transfection of miR-181a-5p or miR-30e-5p mimics re-




Fig. 2 SOX2 is critical for the migration of breast cancer cells. a SOX2 knockdown suppresses the migration of ZR7530 and MDA-MB-231 cells in
the wound-healing assay. b Quantification of cells migrating across the red lines in a. Data are represented as mean ± SD (n = 3 for each group,
p < 0.05). c Down-regulation of SOX2 leads to reduced migration of breast cancer cells through the membrane in the transwell assay. d Quantification
of cells that are present in the lower side of the transwell membrane. Data are represented as mean ± SD (n = 3 for each group, p < 0.05). e The intensity
of dissolved violet staining is correlated with reduced number of cancer cells migrating through the membrane upon SOX2 knockdown. Cells stained with
crystal violet at the lower side of the membrane were lysed and dissolved with acetic acid. The intensity was measured at an absorbance of
560 nm. * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001 vs control, and the error bars indicate the mean ± standard deviation (SD)
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control, respectively (Fig. 5e). More importantly, mu-
tation of these potential binding sites leads to attenu-
ated luciferase activities, suggesting that miR-181a-5p
or miR-30e-5p controls TUSC3 expression through
the binding sites. As expected, SOX2 knockdown
leads to increased protein levels of TUSC3 protein
(Fig. 5f ). Moreover, in the xenografts of SOX2 knock-
down group the transcript levels of SOX2 remain low
and the level of miR-181a-5p or miR-30e-5p are also
significantly lower than the control group (p < 0.05 for
hsa-miR-30e-5p and p < 0.01 for hsa-miR-181a-5p),
suggesting that SOX2 is required for maintaining the
expression of two microRNAs in vivo. In addition, we
did not see significant change of TUSC3 transcript
levels, which is consistent with the finding that the
two microRNA regulate translation but not transcrip-
tion of TUSC3 (Fig. 5g). Taken together, these data
indicate a regulatory axis where SOX2 modulates the
levels of the tumor suppressor protein TUSC3




Fig. 3 SOX2 knockdown reduces the growth and metastasis of breast cancer cells in xenograft models. a Representative xenografts formed by SOX2
knockdown, control and SOX2 overexpression breast cancer cells. Tumours were collected and examined 7 weeks after inoculation of ZR7530 cells.
b-c SOX2 knockdown and SOX2 overexpression significantly reduces and increases the size and weight of xenografts, respectively (n = 5 per cohort,
p< 0.01). d) Representative HE staining of metastatic foci in the lung tissues of BALB/c nude mice 8 weeks after injection with ZR7530 (SOX2 knockdown,
control and SOX2 overexpression). Note the presence of blood vessels (star) in the tumour nodule of control group, arrows point to metastatic areas.
e–f SOX2 knockdown significantly reduces the numbers of tumour nodule initiated by ZR7530 cells and it also reduces the ratio of metastatic tumour
area/total lung area. However, SOX2 overexpression significantly increases the numbers of tumour nodule and the ratio of metastatic tumour area/total
lung area. Data are represented as mean ± SD (n= 5 for each cohort, p< 0.001). * indicates p< 0.05, ** indicates p< 0.01, *** indicates p< 0.001 vs control,
and the error bars indicate the mean ± standard deviation (SD)
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TUSC3 regulates the proliferation, migration and invasion
of breast cancer cells
SOX2 knockdown leads to decreased levels of miR-
181a-5p and miR-30e-5p and increased levels of TUSC3.
To test whether TUSC3 acts as a negative regulator of
proliferation and migration of breast cancer cells, we
performed TUSC3 gain-of-function study (Fig. 6a).
TUSC3 overexpression leads to decreased proliferation
of ZR7530 cells (p < 0.01) (Fig. 6b). In addition, TUSC3
overexpression significantly inhibits the colony forma-
tion efficiency (274 ± 6 Vs 119 ± 4 colonies/well) in 6-well
plates (p < 0.01) and reduces the size of individual colonies
(p < 0.05) (Fig. 6c), suggesting that TUSC3 acts as a nega-
tive regulator of proliferation of breast cancer cells.
We next asked whether increased levels of TUSC3 are
also able to reduce the migration of breast cancer cells.
We first used a wound-healing assay to address the issue
and observed that TUSC3 overexpression significantly
reduced the healing index of ZR7530 cells as compared
to control (24.3% Vs 12.4%) (p < 0.01) (Fig. 6d). We then
used the transwell assay to further test the effect of
TUSC3 overexpression on cell invasion. Similar to
SOX2 knockdown, TUSC3 overexpression dramatically
decreased the invasion capability of ZR7530 (p < 0.01)
(Fig. 6e). Collectively, these results demonstrated that
high levels of TUSC3 protein reduce the invasive po-
tential of breast cancer cells.
Increased SOX2 protein levels correlate with poor survival
in breast cancer patients
Previous studies revealed that approximately 16% of
breast cancer patients exhibit SOX2-positive expression
in clinical samples, and SOX2 is expressed in the early
stage of breast tumours [17]. However, other studies re-
vealed that SOX2 expression was associated with subtypes
and tumour grades of breast cancer [5, 50]. To analyse
whether Sox2 expression level (by probe 214178_s_at)
correlates with distant metastasis free survival in breast
cancer patients, we used the Kaplan-Meier analysis from
IBM SPSS software to analyse the relationship between
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Fig. 4 Decreased SOX2 levels are associated with reduced expression of miR-181a-5p and miR-30e-5p. a Unsupervised hierarchical cluster analysis
of down-regulated miRNAs following SOX2 knockdown. b The decrease in the expression of microRNAs was validated with real-time PCR. Note
the levels of miR-30e-5p are decreased most prominent following SOX2 knockdown. c Cellular activities affected by changes in the levels of microRNAs
following SOX2 knockdown. d Cellular pathways affected by changes in the levels of microRNAs upon SOX2 knockdown. * indicates p < 0.05,
** indicates p < 0.01, *** indicates p < 0.001 vs control, and the error bars indicate the mean ± standard deviation (SD)
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SOX2 protein levels and 5-year survival rates in 471 pa-
tients, and the patients data used for analysis derives from
previous study [51]. As shown in Fig. 7a, SOX2 expression
level significantly converts poor prognosis (Chisquare p-
value = 0.014, Logrank p-value = 0.02268), and the distant
metastasis-free survival of breast cancer patients express-
ing high, middle and low levels of SOX2 protein were
50.4, 70.5 and 78.6%, suggesting that high levels of SOX2
are correlated with poor prognosis in breast cancer pa-
tients. Further analysis revealed that patients with high
and middle levels of SOX2 have a significant worse sur-
vival rate than those with low levels (Fig. 7a, b) (p < 0.05).
However, the survival difference between the middle and
low level groups is not significant (p > 0.05). Moreover, we
found that SOX2 levels are inversely correlated with those
of TUSC3. We examined 12 pairs of normal and breast
cancer biopsies, and found that 9 breast cancer biopsies
have increased expression of SOX2 proteins concomitant
with low levels of TUSC3 (Fig. 7c). In keeping with this
line, high levels of TUSC3 protein were detected in adja-
cent normal tissue samples but were very low in cancer
biopsies (Fig. 7d).
Discussion
High levels of SOX2 proteins have been linked to breast







Fig. 5 SOX2 modulates the expression of TUSC3 through miR-181a-5p and miR-30e-5p. a The sequence of the potential binding sites for miR-181a-5p
and miR-30e-5p in the 3’-UTR of TUSC3. The sites are conserved in human and rodents. b The expression of TUSC3 is repressed by miR-181a-5p and
miR-30e-5p mimics as measured by Western blot analysis. c The application of specific inhibitors against miR-181a-5p and miR-30e-5p increases the
expression of TUSC3 in ZR7530 cells. d Schematic diagram of the binding sites for miR-181a-5p and miR-30e-5p in 3’-UTR of TUSC transcript. Mutated
binding sites (star) were linked with Luciferase reporter (pMIR-Report-Luc). e Mutations of the potential binding sites for miR-181a-5p and miR-30e-5p
lead to increased luciferase activities of TUSC3 reporter. Co-transfection of negative mimics and pMIR-Report-Luc-TUSC3-3UTR-WT construct is used as
control (Con). Mic indicates miR-181a-5p or miR-30e-5p mimics. Mics indicates mixture of miR-181a-5p and miR-30e-5p mimics, ab* indicates both of
a* and b* potential bindings sites are mutated, cd* indicates both of c* and d* potential bindings sites are mutated, and abcd* indicates all
four potential bindings sites are mutated. f SOX2 knockdown leads to increased protein levels of TUSC3. g In xenograft initiated by ZR7530
cells, SOX2 knockdown leads to reduced expression of miR-181a-5p and miR-30e-5p, but not the expression of TUSC3 mRNA. The transcript
levels were measured by examining RNA expression in three individual tumour nodules in each group. * indicates p < 0.05, ** indicates p < 0.01, ***
indicates p < 0.001 vs control, and the error bars indicate the mean ± standard deviation (SD)
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remain largely unknown. Here, we use in vitro and in
vivo models to demonstrate that SOX2 is required for
multiple steps in metastatic processes. We showed that
SOX2 regulates the proliferation, migration and seeding
of breast cancer cells. More importantly, we have identi-
fied a miRNA-mediated regulatory axis downstream of
SOX2 to control these processes. Specifically, we found
that SOX2 regulates the levels of miR-181a-5p and miR-
30e-5p which in turn modulate the levels of the tumor
suppressor TUSC3. Consistently, overexpression of TUSC3
reduces the proliferation and migration of SOX2-high
breast cancer cells.
SOX2 is a key transcription factor important for the
self-renewal of stem cells in multiple tissues including
the trachea and brain [6]. We and others have shown
that SOX2 overexpression promotes the proliferation of
stem cells in the esophagus and lung, leading to
malignancy [15, 33], suggesting that SOX2 acts as an
oncogene. In this study, we found that SOX2 is also re-
quired for the proliferation of breast cancer cells. SOX2
knockdown leads to decreased levels of cell cycle pro-
teins including CCND1, CDK4 and CDK6. Interestingly,
SOX2 knockdown also leads to reduced levels of mul-
tiple microRNAs. We found that the levels of miR-30e-
5p (previously named as miR-30e) are most dramatically
down-regulated upon SOX2 knockdown, which was vali-
dated by real-time PCR. Interestingly, we also found that
miR-181a-5p (previously named as miR-181a) which has
previously been linked to breast cancer development is
also dramatically downregulated. More importantly, fur-
ther analysis using the cytoscape program we found that
miR-30e-5p together with miR-181a-5p co-regulate a
common downstream target, TUSC3. Both miR-30e-5p





Fig. 6 Increased levels of TUSC3 suppress the proliferation and migration of breast cancer cells. a Establishment of cell line (ZR7530) overexpressing
TUSC3. b TUSC3 overexpression leads to reduced proliferation of ZR7530 cells. Data are represented as mean ± SD (n = 3 for each group, p < 0.01).
c TUSC3 overexpression suppresses colony formation efficiency and reduces the size of individual clones in agar assay. Data are represented as
mean ± SD (n = 3 for each group, p < 0.01). d Migration of cancer cells are inhibited by TUSC3 overexpression as revealed by wound healing assay
(p < 0.01). e Overexpression of TUSC3 reduces the invasion capability of ZR7530 cells in the transwell assay (p < 0.01). The cell number present at the
lower side of the membrane of the insert is counted and presented in the graph. * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001 vs
control, and the error bars indicate the mean ± standard deviation (SD)
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of cancer cell growth and migration, invasion and metas-
tasis [52–54]. miR-181a-5p is a member of the miR-
181 s family which includes three other highly conserved
miRNAs, miR-181b, c, and d [55]. Previous studies have
shown increased levels of miR-181a-5p in multiple types
of cancer including ovarian cancer and gastric cancer
[56, 57]. The levels of miR-181a-5p in breast cancer
were recently assessed. While Li et al. demonstrated that
miR-181a-5p is down-regulated in aggressive human
breast and colon cancers [58], a recent study showed
that the levels of miR-181a-5p are high in breast cancer
samples [59]. By contrast, we have just begun to elicit
the role of miR-30e-5p in tumour development. Tissue
microarray analysis suggests that high levels of miR-30e-
5p in primary tumours are associated with a favourable
prognosis in breast cancer [60]. In our study, we ob-
served increased levels of miR-181a-5p and miR-30e-5p
in breast cancer biopsies as compared to normal mam-
mary gland tissue. We found that SOX2 knockdown
leads to decreased levels of miR-181a-5p and miR-30e-5p
accompanied by decreased cell proliferation, suggesting
that these two microRNAs are required for the prolifera-
tion of breast cancer cells.
Consistently, we identified that miR-181a-5p and miR-
30e-5p target the tumor suppressor TUSC3. Overexpres-
sion of these two miRNAs reduces the protein levels of
TUSC3. Moreover, the luciferase assay showed that miR-
181a-5p and miR-30e-5p regulate the 3’-UTR of TUSC3
transcripts. TUSC3 is a putative tumour suppressor
often lost in epithelial cancers e.g. ovarian cancer and
head and neck squamous cell carcinomas [47, 61]. Pro-
moter methylation leading to silencing of TUSC3 gene
was considered as a poor prognostic factor in ovarian
cancer [48]. Here, we show decreased but not complete
loss of TUSC3 protein in breast cancers, suggesting that
promoter methylation is unlikely a significant con-
tributor to disease progression. We found that the pro-
tein levels of TUSC3 are decreased in breast tumour
tissues as compared to surrounding normal tissues. In
addition, overexpression of TUSC3 decreases the pro-
liferation and migration capabilities of breast cancer
cells. These findings are consistent with the tumor
suppressor function of TUSC3 [62]. TUSC3 is an im-
portant component of the oligosaccharyltransferase
(OST) complex that catalyzes N-linked glycosylation of
proteins in the endoplasmic reticulum (ER) [63, 64].
Loss of TUSC3 in mammalian cells leads to accumula-
tion of unfolded or misfolded proteins in the ER,
resulting in ER stress. In ovarian cancer cells loss of
TUSC3 induces ER stress and morphological alter-
ations in the ER. Interestingly, ovarian cancer cells
lacking TUSC3 seem able to alleviate the massive ER
stress response through the PERK-mediated adaptive




Fig. 7 Expression of SOX2 and TUSC3 in human breast cancer samples. a High levels of SOX2 are correlated with poor distant metastasis-free
survival. b Patient survival time and its correlation with SOX2 expression levels. c High levels of SOX2 protein are present in representative breast
cancer sample which has low levels of TUSC3 (n = 9 pairs). Note the normal breast tissue expresses relatively high levels of TUSC3. d Breast cancer
biopsies express very low levels of TUSC3 protein as compared to adjacent normal tissues. Biopsies were taken from three patients
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accumulated unfolded proteins in cancer cells induce
the unfolded protein response (UPR), facilitating can-
cer cells to adapt to ER stress [66]. miR-181a-5p over-
expression has been shown to promote ER stress and
leads to myogenic differentiation in C2C12 cells [67].
Along these lines our study indicates that high levels
of TUSC3 expression may induce a cellular response
of breast cancer cells, resulting in reduced cell prolifer-
ation and migration.
Previous studies revealed that SOX2 protein levels are
correlated with the overall survival of patients with mul-
tiple types of cancer including esophageal [33] and lung
cancer [24]. Moreover, SOX2 protein has been assessed
as a diagnostic marker and therapeutic target for mul-
tiple cancer treatments [68–70]. Our results suggest that
high levels of SOX2 protein are associated with poor
prognosis of breast cancer.
Conclusions
In summary, we showed in this study that SOX2 pro-
tein is critical for the proliferation, migration and me-
tastasis of breast cancer. We identified that SOX2
exerts these functions through miR-181a-5p and miR-
30e-5p which share a common downstream target, the
putative tumour suppressor TUSC3 (Fig. 8). Knock-
down SOX2 leads to decreased levels of miR-181a-5p
and miR-30e-5p accompanied by increased levels of
TUSC3. Consistently, overexpression of TUSC3 sup-
presses the proliferation and migration of breast cancer
cells. Together these findings support a regulatory axis
orchestrated by high levels of SOX2, and this axis is
critical for breast cancer development. In future studies
it will be interesting to explore potential avenues to tar-
get this SOX2/microRNA/TUSC3 axis for therapeutic
gains.
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